Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

[1]  René Bernards,et al.  MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology. , 2019, The Journal of molecular diagnostics : JMD.

[2]  F. Cardoso,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[4]  C. Perou,et al.  Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. , 2018, Cancer treatment reviews.

[5]  O. Myklebost,et al.  Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples , 2018, PloS one.

[6]  J. Bartlett,et al.  Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores , 2017, PloS one.

[7]  P. Whitworth,et al.  Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) , 2017, Annals of Surgical Oncology.

[8]  P. Nuciforo,et al.  HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. , 2017, The Lancet. Oncology.

[9]  Benjamin Haibe-Kains,et al.  The molecular basis of breast cancer pathological phenotypes , 2017, The Journal of pathology.

[10]  P. Whitworth,et al.  Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping , 2016, Annals of Surgical Oncology.

[11]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[12]  Carlos Caldas,et al.  Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer , 2016, Biomarker insights.

[13]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[14]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[15]  P. Whitworth,et al.  Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) , 2014, Annals of Surgical Oncology.

[16]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[17]  A. Glas,et al.  MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. , 2014, The Journal of molecular diagnostics : JMD.

[18]  Diederik Wehkamp,et al.  Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature. , 2013, Personalized medicine.

[19]  J. Wesseling,et al.  A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study , 2013, International journal of cancer.

[20]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S Michiels,et al.  Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E. van Limbergen,et al.  Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Mardis,et al.  A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.

[24]  Jason S. Carroll,et al.  A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response , 2012, Breast Cancer Research and Treatment.

[25]  N. Esposito,et al.  A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas , 2012, Modern Pathology.

[26]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[27]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[28]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[29]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[30]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[31]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Glas,et al.  Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial , 2017, Breast Cancer Research and Treatment.

[33]  S. Mook,et al.  Prognostic factors in breast cancer: one fits all? , 2011 .

[34]  Yunlong Liu,et al.  BMC Genomics BioMed Central Methodology article , 2005 .